RevolKa Ltd. Announces Milestone Achievement in Collaborative Research with Sumitomo Pharma Co., Ltd.

RevolKa Ltd., a biotech company, has announced the completion of its collaborative drug discovery project with Sumitomo Pharma Co. for rare diseases. The project was completed within the agreed time frame and lead candidates were identified using RevolKa's proprietary technology platform called aiProtein®, which integrates directed protein evolution technology with artificial intelligence (AI). These lead candidates remarkably exceeded the criteria set in the project, and Sumitomo Pharma will receive a right of first refusal to an exclusive license of the molecules. Specific financial terms were not disclosed.

RevolKa's aiProtein® is an AI-assisted directed evolution of proteins that can evolve more than two functions simultaneously, making it a powerful tool for creating novel and highly optimized proteins for pharmaceutical and industrial uses. The company was founded in April 2021 by academic and industry experts in biotechnology and AI, with headquarters located in Tokyo, Japan.

RevolKa Ltd., Sumitomo Pharma Co., rare diseases, aiProtein®, protein engineering

RevolKa Ltd. announces successful completion of collaborative drug discovery project with Sumitomo Pharma Co. for